Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Neumora Therapeutics, Inc. ( (NMRA) ) is now available.
On January 12, 2026, Neumora Therapeutics made a new corporate presentation available for use at the 44th Annual J.P. Morgan Healthcare Conference, outlining its mission to redefine neuroscience drug development and its plan to advance three core franchises in metabolic, neurodegenerative and neuropsychiatric diseases. The materials highlight a broad pipeline led by NMRA-215, a differentiated oral NLRP3 inhibitor for obesity expected to enter the clinic in the first half of 2026 with initial biomarker and proof-of-concept data targeted by late 2026, alongside programs in Alzheimer’s-related agitation, Parkinson’s disease, ALS and major depressive disorder, and indicate that the company expects multiple data readouts and program updates during 2026 and has sufficient cash to fund operations into the third quarter of 2027, positioning it for a catalyst-rich period that could influence its standing in the competitive obesity and CNS therapeutics markets.
The most recent analyst rating on (NMRA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Neumora Therapeutics, Inc. stock, see the NMRA Stock Forecast page.
Spark’s Take on NMRA Stock
According to Spark, TipRanks’ AI Analyst, NMRA is a Neutral.
The score is held down primarily by weak financial performance (no revenue, large losses, and significant cash burn) despite low leverage. Technicals are moderately supportive with the stock trading above key moving averages, and recent positive pipeline events provide upside optionality, but valuation is constrained by ongoing losses and no dividend.
To see Spark’s full report on NMRA stock, click here.
More about Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc. is a neuroscience-focused biopharmaceutical company developing brain-penetrant small-molecule therapies across neuropsychiatric, neurodegenerative and metabolic diseases, targeting large indications such as obesity, major depressive disorder, schizophrenia, Alzheimer’s disease and Parkinson’s disease. Its pipeline spans multiple clinical and preclinical programs, including lead candidates like NMRA-215 for obesity and related metabolic diseases, NMRA-511 for agitation in Alzheimer’s disease, several assets for Parkinson’s and ALS, and neuropsychiatric candidates such as navacaprant and M4 modulators, reflecting a strategy to address major unmet needs in large, high-burden markets.
Average Trading Volume: 2,119,591
Technical Sentiment Signal: Hold
Current Market Cap: $389.3M
Find detailed analytics on NMRA stock on TipRanks’ Stock Analysis page.